TNFSF10 and glioblastoma: Co-administration of TRAIL with bortezomib (a proteasome inhibitor) to TRAIL-resistant GBM cell lines and to primary tumors showed a synergistic effect to induce apoptosis through the inactivation of the NF-κB transcription factor [323].